1st Trend line - ALRNThis is my first take on drawing a trend line for ALRN. Please provide comment and feedback. Thank you.
0%
0%
0%
0%
0%
About Aileron Therapeutics, Inc
Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Manuel C. Alves Aivado
Website
aileronrx.com
Headquarters
Waltham
Employees
6
Founded
2001
ISIN
US00887A2042
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Waltham, MA.
ALRN Possible Bullish Breakout ALRN is Hot right now and posted big gains in After Hours Friday, we should see continued momentum and further upside
ALRN Weekend Data CatalystALRN had some weekend news. Will be interesting to see if it can break above a near-two-year resistance level. I didn't show it all the way back to November of 2018 but if you take the chart out further, you can see this level holding as resistance.
"Saturday, the company announced new positive cl
ALRN long swingThe price tested the trendline and the 50 day ma to close above the .23 fibonacci level and right on the 20 day EMA. Resistance at 1.38, first target of 1.48 second at 1.68
$ALRN Upside continuation targets Multiple upgrades post earnings
JonesTrading analyst Soumit Roy reiterated a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. The company’s shares closed last Tuesday at $0.66.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 12.4% and a 4
Recent insider buying Recent & repeated insider buying. Company expanding cancer trial with $PFE palbociclib & will report full dataset in Q2 2020. Trading below cash.
$ALRN Looking for a 1-2 dollar move.On a Beginning start of a TOP pattern this could be a dollar move and make a quick 50$+ depending on trade size of course.
TOP patterns are vary reliable but we are looking at the past and the Volume and float also. its looking good. lets see how this runs make sure
you add a stop lose to your chart
See all ideas
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
